Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.

表 ST1：概述了针对去氧咖啡酸（neocuproine）或MEKi（binimetinib）及其对人源原代细胞系进行生长抑制IC50值（包括相应的95%置信区间（C.I.95%））的实验结果。该表同时列出了已确认的致癌突变以及去氧咖啡酸标准化与MEKi反应比值的比较。